Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of bevacizumab with radiotherapy and temozolomide for children with a high grade glioma (HERBY)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at bevacizumab, radiotherapy and chemotherapy after surgery for children with a type of brain tumour called a high grade glioma.
It was for children who had a tumour that wasn’t in the hindbrain (cerebellum) or brain stem.
The trial was for children from 3 years old, up to and including the age of 17. We use the term ‘you’, but of course if you are a parent, we are referring to your child.
More about this trial
In this trial, doctors wanted to see if adding bevacizumab improved treatment.
Bevacizumab is a type of targeted cancer drug called a monoclonal antibody. It works by targeting a protein called
All cancers need a blood supply to be able to survive and grow. Blocking VEGF can stop the growth of new blood vessels and slow the growth of a tumour.
Doctors already use bevacizumab to treat different types of adult cancers.
The aim of the trial was to see if adding bevacizumab to radiotherapy and temozolomide helped children with high grade gliomas
Summary of results
- 59 children and young people had radiotherapy and temozolomide
- 62 children and young people had radiotherapy, temozolomide and bevacizumab
- just over 11½ months (11.8 months) for those who had radiotherapy and temozolomide
- just over 8 months (8.2 months) for those who had radiotherapy, temozolomide and bevacizumab
The team are also looking at the average length of time they live after their treatment. Researchers will continue to follow up the children and young people to find this out. When these results are available we will update this summary to include them.
27 children and young people in the temozolomide only group had severe side effects. And 3 stopped treatment due to the severe side effects.
35 children and young people in the bevacizumab group had severe side effects. And 13 stopped treatment due to the severe side effects.
The trial team concluded that adding bevacizumab to radiotherapy and temozolomide didn’t improve how long these children and young people were alive and had no sign of their tumour.
This isn’t the same for adults with a high grade glioma. And the trial team says this highlights the importance of doing these trials for children and young people.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer